Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade. On this Form 4, Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals, so the sale reflects only a portion of the director’s overall stake.

Insider Trade Summary 10b5-1

Net Seller: 4,386 shares ($15,526)

Net Sell 1 txn

Insider Bumpus Namandje

Role null

Sold 4,386 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	4,386	$3.54	$16K

Holdings After Transaction: Class A Common Stock — 43,171 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 4,386 shares Sale price: $3.54 per share Shares held after transaction: 43,171 shares +1 more

4 metrics

Shares sold 4,386 shares Open-market sale of Class A Common Stock

Sale price $3.54 per share Average price for the 4,386-share sale

Shares held after transaction 43,171 shares Director’s direct holdings following the sale

Rule 10b5-1 plan adoption date March 3, 2026 Plan governing the reported sale

Key Terms

Form 4, Rule 10b5-1 trading plan, open-market sale, Class A common stock

4 terms

Form 4 regulatory

"reported selling 4,386 shares of Recursion Pharmaceuticals Class A common stock at an average price of $3.54 per share, documented as a routine insider trading disclosure on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Rule 10b5-1 trading plan regulatory

"The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"Bumpus reported an open-market sale of 4,386 shares of Class A common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A common stock financial

"Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 05:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bumpus Namandje

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/03/2026		S⁽¹⁾		4,386	D	$3.54	43,171	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Recursion Pharmaceuticals (RXRX) director Namandje Bumpus report on this Form 4?

Director Namandje Bumpus reported selling 4,386 shares of Recursion Pharmaceuticals Class A common stock. The transaction was an open-market sale at an average price of $3.54 per share, documented as a routine insider trading disclosure on Form 4.

How many RXRX shares did Namandje Bumpus sell and at what price?

Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals Class A common stock at an average price of $3.54. This represents a single open-market sale transaction, as disclosed in the Form 4 insider trading report filed with the SEC.

How many Recursion Pharmaceuticals shares does Namandje Bumpus hold after the sale?

After the reported sale, Namandje Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals Class A common stock. This shows the director retained a sizable position following the 4,386-share open-market sale disclosed in the Form 4 filing.

Was the RXRX insider sale by Namandje Bumpus under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026. Such plans pre-schedule trades, reducing the significance of the exact timing of this 4,386-share open-market sale.

Is the Namandje Bumpus Form 4 sale a buy or a sell signal for RXRX investors?

The filing shows a sale, not a purchase, of 4,386 shares at $3.54. However, the transaction occurred under a pre-arranged Rule 10b5-1 plan and Bumpus still holds 43,171 shares, suggesting a routine diversification rather than a clear directional signal.